AngioDynamics (NASDAQ:ANGO) Announces Quarterly Earnings Results, Beats Expectations By $0.16 EPS

AngioDynamics (NASDAQ:ANGO) released its quarterly earnings data on Wednesday. The medical instruments supplier reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.16, Zacks reports. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The firm had revenue of $72.00 million during the quarter, compared to analyst estimates of $70.30 million. The business’s revenue for the quarter was down 4.3% on a year-over-year basis. AngioDynamics updated its FY 2025 guidance to -0.340–0.310 EPS and its FY25 guidance to ($0.34)-($0.31) EPS.

AngioDynamics Trading Up 12.4 %

Shares of NASDAQ ANGO opened at $10.86 on Thursday. The firm has a fifty day simple moving average of $10.28 and a two-hundred day simple moving average of $8.85. The firm has a market capitalization of $439.46 million, a PE ratio of -1.93 and a beta of 0.56. AngioDynamics has a 12 month low of $5.47 and a 12 month high of $13.50.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright raised their target price on AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 10th.

Insider Activity

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the firm’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the sale, the senior vice president now directly owns 41,817 shares in the company, valued at $514,767.27. This trade represents a 8.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 5.40% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.